Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo

Li,Wei; Liu,Mei-Lin; Cai,Jia-Hui; Tang,Yun-Xian; Zhai,Ling-Yun; Zhang,Jun

doi:10.3892/ol.2012.688

Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo

Authors:
- Wei Li
- Mei-Lin Liu
- Jia-Hui Cai
- Yun-Xian Tang
- Ling-Yun Zhai
- Jun Zhang
View Affiliations

Affiliations: Department of Gynecology, Nanjing Medical University of Hangzhou Hospital, Hangzhou, Zhejiang 310006, P.R. China
Published online on: April 23, 2012 https://doi.org/10.3892/ol.2012.688
Pages: 168-174

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was designed to investigate the effects of a cyclooxygenase (COX)-1 inhibitor, SC-560, administered in combination with taxol, on the molecular mechanisms of antitumor efficacy in a SKOV-3 human ovarian carcinoma cell xenograft-bearing mouse model. The mice were treated with 6 mg/kg/day SC-560 by gavage twice every other day and20 mg/kg taxol by intraperitoneal injection once a week for three weeks. Microvessel density (MVD) and vascular endothelial growth factor (VEGF) mRNA levels of ovarian cancer were detected in the tumor tissues using immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR), respectively. The index of proliferating and apoptotic cells in the tumor tissues was determined by staining for Ki-67 and using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method, respectively. On day 7 after the end of administration, the tumor volume of mice in the combination group was reduced by 55.35% compared with that of the control mice, and the difference was statistically significant (P<0.05). In the combination group, the expression of VEGF, MVD and the cell proliferation index were inhibited significantly, while the apoptotic index was notably increased (all P<0.01, compared with the control group). Our results indicate that the molecular mechanisms of the antitumor efficacy of SC-560 combined with taxol therapy may act in part by inhibiting tumor angiogenesis, reducing cell proliferation and inducing cell apoptosis.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
3	Jain A, Dubashi B, Reddy KS and Jain P: Weekly paclitaxel in ovarian cancer - the latest success story. Curr Oncol. 18:16–17. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kumar S, Mahdi H, Bryant C, Shah JP, Garg G and Munkarah A: Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health. 2:411–427. 2010. View Article : Google Scholar : PubMed/NCBI
5	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar
6	Bijman MN, Hermelink CA, van Berkel MP, Laan AC, Janmaat ML, Peters GJ and Boven E: Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem Pharmacol. 75:427–437. 2008. View Article : Google Scholar : PubMed/NCBI
7	Munkarah AR, Ali-Fehmi R, Jiang JZ, Elhammady E, Malone JM Jr and Saed GM: The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer. Anticancer Drugs. 18:889–896. 2007.PubMed/NCBI
8	Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 38:97–120. 1998. View Article : Google Scholar
9	Smith WL, Garavito RM and DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases) -1 and -2. J Biol Chem. 271:33157–33160. 1996. View Article : Google Scholar : PubMed/NCBI
10	Li W, Ji ZL, Zhuo GC, Xu RJ, Wang J and Jiang HR: Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice. Med Oncol. 27:98–104. 2010. View Article : Google Scholar : PubMed/NCBI
11	Dore M, Cote LC, Mitchell A and Sirois J: Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J Histochem Cytochem. 46:77–84. 1998. View Article : Google Scholar : PubMed/NCBI
12	Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN and Dey SK: Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 65:3735–3744. 2005. View Article : Google Scholar : PubMed/NCBI
13	Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC and Dey SK: Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res. 66:2527–2531. 2006. View Article : Google Scholar : PubMed/NCBI
14	Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, Orsulic S, Morrow JD, Dubois RN and Dey SK: Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res. 67:5285–5292. 2007. View Article : Google Scholar
15	Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK and DuBois RN: Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 63:906–911. 2003.PubMed/NCBI
16	Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ and Dey SK: Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology. 142:3198–3206. 2001.PubMed/NCBI
17	Williams CS, Watson AJM, Sheng H, Helou R, Shao J and DuBois RN: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60:6045–6051. 2000.PubMed/NCBI
18	Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M and Kudo T: Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int J Cancer. 73:33–37. 1997. View Article : Google Scholar : PubMed/NCBI
19	Li W, Xu RJ, Jiang LH, Shi JF, Long X and Fan B: Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma. Med Oncol. 22:63–70. 2005. View Article : Google Scholar : PubMed/NCBI
20	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 84:1875–1887. 1992. View Article : Google Scholar : PubMed/NCBI
21	Kitamura T, Itoh M, Noda T, Matsuura M and Wakabayashi K: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer. 109:576–580. 2004. View Article : Google Scholar : PubMed/NCBI
22	Ferrara N, Leung DW, Cachianes G, Winer J and Henzel WL: Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. Methods Enzymol. 198:391–405. 1991. View Article : Google Scholar : PubMed/NCBI
23	Bernard MP, Bancos S, Sime PJ and Phipps RP: Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des. 14:2051–2060. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD and Munkarah AR: The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer. 98:1423–1429. 2003. View Article : Google Scholar : PubMed/NCBI
25	Khunnarong J, Tangjitgamol S, Manusirivithaya S, Suekwattana P and Leelahakorn S: Expression of cyclooxygenase-1 in epithelial ovarian cancer: a clinicopathological study. Asian Pac J Cancer Prev. 9:757–762. 2008.PubMed/NCBI
26	Urick ME, Giles JR and Johnson PA: VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer. Gynecol Oncol. 110:418–424. 2008. View Article : Google Scholar : PubMed/NCBI
27	Li W, Wang J, Jiang HR, Xu XL, Zhang J, Liu ML and Zhai LY: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int J Mol Sci. 12:668–681. 2011. View Article : Google Scholar : PubMed/NCBI
28	Harlozinska A, Sedlaczek P, Kulpa J, Grybos M, Wójcik E, Van Dalen A and Einarsson R: Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res. 24:1149–1157. 2004.PubMed/NCBI
29	Prager GW and Poettler M: Angiogenesis in cancer. Basic mechanisms and therapeutic advances. Hamostaseologie. 32:Aug 12–2011.(Epub ahead of print).
30	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
31	Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:303–324. 1993. View Article : Google Scholar : PubMed/NCBI
32	Li L, Wang L, Zhang W, Tang B, Zhang J, Song H, Yao D, Tang Y, Chen X, Yang Z, et al: Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 24:1973–1979. 2004.PubMed/NCBI
33	Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H and Mori T: Expression of vascular endothelial growth factor (VEGF) in epithelia ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br J Cancer. 76:1221–1227. 1997. View Article : Google Scholar : PubMed/NCBI
34	von Rahden BH, Stein HJ, Pühringer F, Koch I, Langer R, Piontek G, Siewert JR, Höfler H and Sarbia M: Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res. 65:5038–5044. 2005.PubMed/NCBI
35	Li W, Xu RJ, Lin ZY, Zhuo GC and Zhang HH: Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor. Med Oncol. 26:170–177. 2009. View Article : Google Scholar
36	Li Y, Guo Z, Han YP and Guo XY: Expressions of MVD, VEGF, Ki67 in residual prostate cancer after cryoablation. Clin Oncol Cancer Res. 8:27–32. 2011.
37	Zhou YJ, Xiong YX, Wu XT, Shi D, Fan W, Zhou T, Li YC and Huang X: Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol. 10:3225–3229. 2004.PubMed/NCBI
38	Wang J, Lv F, Fei X, Cui Q, Wang L, Gao X, Yuan Z, Lin Q, Lv Y and Liu A: Study on the characteristics of contrast-enhanced ultrasound and its utility in assessing the microvessel density in ovarian tumors or tumor-like lesions. Int J Biol Sci. 7:600–606. 2011. View Article : Google Scholar : PubMed/NCBI
39	Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR and Buller RE: The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res. 11:3733–3742. 2005. View Article : Google Scholar : PubMed/NCBI
40	Guşet G, Costi S, Lazăr E, Dema A, Cornianu M, Vernic C and Păiuşan L: Expression of vascular endothelial growth factor (VEGF) and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma. Rom J Morphol Embryol. 51:677–682. 2010.PubMed/NCBI
41	Cantu De León D, Lopez-Graniel C, Frias Mendivil M, Chanona Vilchis G, Gomez C and De La Garza Salazar J: Significance of microvascular density (MVD) in cervical cancer recurrence. Int J Gynecol Cancer. 13:856–862. 2003.PubMed/NCBI
42	Meresman G: Relevance of apoptosis in the female reproductive system. Invest Clin. 52:274–290. 2011.PubMed/NCBI
43	Forones NM, Carvalho AP, Giannotti-Filho O, Lourenço LG and Oshima CT: Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia. Arq Gastroenterol. 42:30–34. 2005. View Article : Google Scholar : PubMed/NCBI
44	Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP and Saed GM: Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig. 9:168–173. 2002. View Article : Google Scholar : PubMed/NCBI
45	Kumar S, Mahdi H, Bryant C, Shah JP, Garg G and Munkarah A: Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health. 2:411–427. 2010. View Article : Google Scholar : PubMed/NCBI